.jpg)
ABOUT HOOMYA
關于宏雅
湖南宏雅基因技術有限公司是由臨床藥理學家、我國遺傳藥理學與藥物基因組學的開拓者和奠基人、個體化醫(yī)學的倡導者和引領者周宏灝院士及其團隊發(fā)起設立，致力于個體化醫(yī)學（精準醫(yī)學）檢測技術的研究與產(chǎn)業(yè)化的高科技公司。公司主要從事個體化醫(yī)學檢測產(chǎn)品（含產(chǎn)品科研、CDMO、儀器與設備、試劑耗材及檢測服務）的開發(fā)、運營與市場推廣，打造精準醫(yī)學時代的專業(yè)個體化醫(yī)學檢測運營服務平臺.
公司聯(lián)合以湘雅醫(yī)學檢驗所為主體的國內外多家個體化醫(yī)學（精準醫(yī)學)專業(yè)研究機構，引進頂尖學者、
美國墨菲特癌癥中心醫(yī)學主任霍華德 · L · 麥克勞德為代表的專家技術團隊，整合國內外先進的個體化醫(yī)學檢測技術平臺，
以研發(fā)帶動生產(chǎn)和銷售，依托具有先進性的分子診斷核心技術，在體外診斷，尤其是高端的分子診斷領域形成了
一系列具有自主知識產(chǎn)權的產(chǎn)品。
The company has joined forces with a number of Personalized medicine (precision medicine) professional research institutes at home and abroad, mainly based on the Xiangya medical laboratory, howard L. McCloud, medical director of the Murphy Cancer Center in the United States and a leading scholar, was brought in to represent the expert and technical team to integrate advanced Personalized medicine detection technology platforms at home and abroad, a series of products with independent intellectual property rights have been developed in the field of in vitro diagnosis, especially in high-end molecular diagnosis.
公司目前主營業(yè)務包括各類應用于無創(chuàng)產(chǎn)前篩查、疾病預測、疾病早期篩查、疾病早期分子診斷與分
子分型、疾病個體化用藥指導、疾病預后監(jiān)測的分子檢測產(chǎn)品，已形成覆蓋全國的營銷網(wǎng)絡，成為個體化
醫(yī)學（精準醫(yī)學）專業(yè)服務領域的優(yōu)勢品牌企業(yè)。
At present, the company's main business includes various applications in non-invasive prenatal screening, disease prediction, disease early screening, disease early molecular diagnosis and classification, the molecular detection products of sub-typing, disease individualized medication guidance and disease prognosis monitoring have formed a nationwide marketing network and become individualized, medical (precision medicine) professional services in the field of dominant brand enterprises
公司聯(lián)合以湘雅醫(yī)學檢驗所為主體的國內外多家個體化醫(yī)學（精準醫(yī)學）專業(yè)研究機構，引進以
頂尖學者、美國墨菲特癌癥中心醫(yī)學主任霍華德 · L · 麥克勞德d為代表的專家技術團隊，整合
國內外先進的個體化醫(yī)學檢測技術平臺，以研發(fā)帶動生產(chǎn)和銷售，依托具有先進性的分子診斷核心技術，
在體外診斷，尤其是高端的分子診斷領域形成了一系列具有自主知識產(chǎn)權的產(chǎn)品。
The company has teamed up with a number of Personalized medicine (precision medicine) professional research institutes at home and abroad, mainly based on the Xiangya medical laboratory, howard L. McCloud D, medical director of the Murphy Cancer Center and a leading scholar, is the representative of the expert and technical team, which integrates the advanced Personalized medicine detection technology platform at home and abroad, in vitro diagnosis, especially in high-end molecular diagnosis field, has formed a series of products with independent intellectual property rights, relying on advanced molecular diagnosis core technology.
公司目前主營業(yè)務包括各類應用于無創(chuàng)產(chǎn)前篩查、疾病預測、疾病早期篩查、疾病早期分子診斷與分子
分型、疾病個體化用藥指導、疾病預后監(jiān)測的分子檢測產(chǎn)品，業(yè)務版圖已遍布湖南、湖北、江蘇、浙
江、安徽、上海、北京、天津、河南、河北、山東、山西、陜西、遼寧、廣東、廣西、云南、
貴州等地區(qū)。
At present, the company's main business includes various applications in non-invasive prenatal screening, disease prediction, disease early screening, disease early molecular diagnosis and molecular, molecular testing products for typing, individualized medication guidance, and disease prognosis monitoring, the business scope has spread over Hunan, Hubei, Jiangsu, Zhejiang, Anhui, Shanghai, Beijing, Tianjin, Henan, Hebei, Shandong, Shanxi, Shaanxi, Liaoning, Guangdong, Guangxi, Yunnan, Guizhou and other regions.
個體化醫(yī)學Personalized Medicine
個體化醫(yī)學是21世紀醫(yī)學發(fā)展的必然趨勢。隨著人類基因組計劃的完成和后基因組學的深入研究， 越來越多的致病基因被定位，更多疾病發(fā)生的遺傳學基礎得以闡明，與人類生理、病理以及藥物效應 和毒副反應相關的基因特征不斷被揭示，促使醫(yī)學模式由經(jīng)典的基于規(guī)律總結的“標準化醫(yī)學”，向基 于個體基因差異進行的“量體裁衣”式的“個體化醫(yī)學”轉變。個體化醫(yī)學是根據(jù)個體的基因信息對疾病 進行診斷、治療和風險評估，使疾病的診治更為精確、高效，顯著提升醫(yī)療質量。個體化醫(yī)學目前發(fā) 展最為成熟的領域是個體化用藥，即以每個患者的基因信息為基礎決定個人的藥物治療方案，從基因 組成或表達的差異來預測疾病的治療效果或毒副作用，對每個患者選擇最適宜的藥物療法進行治療。 個體化醫(yī)學彌補了循證醫(yī)學的缺點，其治療更有針對性，可以按照個體對某種特定疾病易感性的不同 或對某種特定治療反應性的不同，把人群分為不同的亞群，進而對患者進行有效地預防或治療性干預， 節(jié)約醫(yī)療費用和避免毒副反應Personalized medicine is an inevitable trend in the development of medicine in the 21st century.With the completion of the human genome project and in-depth research on post-genomics, more and more disease-causing genes have been located, and the genetic basis of more diseases has been elucidated, which is related to human physiology, pathology, drug effects and toxic side effects. Gene characteristics are constantly being revealed, prompting the medical model to change from the classic "standardized medicine" based on rule summaries to "tailor-made" "individualized medicine" based on individual genetic differences.Personalized medicine is the diagnosis, treatment and risk assessment of diseases based on individual genetic information, making the diagnosis and treatment of diseases more accurate and efficient, and significantly improving the quality of medical care.The most mature field of personalized medicine is personalized medicine, which determines individual drug treatment plans based on each patient'。
個體化醫(yī)學檢測Personalized Medicine
通過利用專業(yè)檢測儀器平臺和配套的試劑、耗材，檢測與疾病的發(fā)生和用藥相關基因的結構改變、表達 和代謝變化等，進一步使用數(shù)據(jù)庫、分析模型、軟件等工具對檢測結果進行專業(yè)分析并對分析結果進行專業(yè) 咨詢（針對受檢者及其醫(yī)生），對疾病進行個性化的預測、診斷、治療決策和檢測的臨床檢測服務。